Posts tagged: human

Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica. Curr Neurovasc Res

Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica Sudhakar Reddy Kalluri, MSc; Zsolt Illes, MD; Rajneesh Srivastava, MSc; Bruce Cree, MD; Til Menge, MD; Jeffrey L. Bennett, MD, PhD; Achim Berthele, MD; Bernhard Hemmer, MD Arch Neurol.

With a concentration of 55,000 mM, water is by far the most prevalent molecule in biological systems.

Water channel aquaporin-4 (AQP4) is expressed in astrocytes throughout brain and spinal cord. Two major AQP4 isoforms are expressed, M1 and M23, having different translation initiation sites

Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system associated with autoantibodies against the glial water channel protein aquaporin-4. It has recently been reported that immunoglobulin from neuromyelitis optica patients injected peripherally does not cause lesions in naive rats, but only when pre-existing central nervous system inflammation is present

Objective In neuromyelitis optica (NMO), the destruction of the blood-brain barrier (BBB) has been considered to be the first step of the disease process.

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of spinal cord and optic nerve caused by pathogenic autoantibodies (NMO-IgG) against astrocyte aquaporin-4 (AQP4). We developed a high-throughput screen to identify blockers of NMO-IgG binding to human AQP4 using a human recombinant monoclonal NMO-IgG and transfected Fisher rat thyroid cells stably expressing human M23-AQP4

BACKGROUND: Recently, a highly specific serum autoantibody was discovered in patients with neuromyelitis optica, called NMO-IgG, and aquaporin-4, the most abundant water channel in the CNS, was identified as the target antigen.

Interferon (IFN)-β is the treatment most often prescribed for relapsing–remitting multiple sclerosis (RRMS). 30–50% of MS patients, however, do not respond to IFN-β

In the past 10 years, neuromyelitis optica (NMO) has evolved from Devic’s categorical clinical description into a broader disease spectrum. Serum IgG antibodies have been identified in NMO patients with the water channel aquaporin-4 (AQP4) as their main target antigen.

Background and Goals: Neuromyelitis optica (NMO) is associated with aquaporin-4 (AQP4)-specific IgG1 antibodies. Human IgG1 is a T cell-dependent antibody subclass, which suggests that AQP4-specific T cells may participate in NMO pathogenesis, a possibility also supported by observations that AQP4-specific antibodies are pathogenic only in the presence of CNS inflammation. We have been studying T cell recognition of AQP4 in NMO patients and in mice in order to understand the potential role of T cells in NMO pathogenesis and to develop a model of NMO.

Background: Neuromyelitis optica (NMO) is characterized by severe optic neuritis and transverse myelitis. Aquaporin-4 (AQP4) antibody is a diagnostic biomarker of NMO